NASDAQ:CGON
CG Oncology, Inc.
CG Oncology, Inc.'s revenue grew 254.7% in fiscal 2025 to $4.0M while operating margin rose to −4722.1%, its highest in 3 years. Free cash flow was −$132.5M, −3279.2% of revenue, and the diluted share count rose 23.7%.Summary generated from CG Oncology, Inc.'s SEC filings. Latest annual report filed Feb 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$4.0M
Revenue growth+254.7%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−4722.1%
Net margin−3985.0%
ROIC−25.1%
Return on equity−21.7%
Debt / equity0.00
Free cash flow−$132.5M
FCF margin−3279.2%
Share count change+23.7%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0 | 1 | 4 |
| Operating income | −55 | −115 | −191 |
| Net income | −49 | −88 | −161 |
| Free cash flow | n/a | −79 | −132 |
Recent filings
- 4Insider transaction report
Sep 17, 2026 - 4Insider transaction report
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KResults of a shareholder vote
Jun 8, 2026 - 8-KDirector or officer change
May 26, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 8, 2026 - 8-KResults of operations and financial condition
May 8, 2026